GENENTA TECHNOLOGY
Cell-based technology for
safe tumor treatments
Our proprietary technology centers on a transgene expression control vector that provides dual control at the transcriptional and post-transcriptional level. Together these ensure therapeutics are released within the tumor and limit systemic toxicity.
A Tie-2 promoter ensures the transgene transcription occurs in TEMs, while miRNA-126 target sequences inhibit expression of the transgene in hematopoietic stem and progenitor cells.
